Neovacs S.A. (0LW1)

Overview

Neovacs S.A. is a pioneering biotechnology company based in Paris, France, established in 1993. It is dedicated to advancing the field of therapeutic vaccines with a primary focus on treating a range of autoimmune, inflammatory, allergy, and cancer diseases. Leveraging its innovative Kinoid technology, Neovacs is at the forefront of developing new treatments that aim to bring long-lasting relief to patients suffering from these chronic conditions. The company's research and clinical trials reflect its commitment to addressing the unmet medical needs in these domains.

Products and Services

• IFNa Kinoid

  This is an anti-interferon alpha vaccine developed by Neovacs, currently in Phase IIb clinical trial targeted at lupus erythematosus. Designed to combat the effects of interferon alpha, a protein involved in the inflammation process of lupus, IFNa Kinoid represents a promising step forward in the treatment of this challenging autoimmune disease. Additionally, it's in a Phase IIa clinical trial for dermatomyositis, indicating its potential applicability across multiple autoimmune conditions.

• IL-4/IL-13 Kinoid

  In the preclinical stage of development, the IL-4/IL-13 Kinoid is an innovative therapeutic vaccine aimed at treating allergies. Focusing on the interleukin pathways, particularly IL-4 and IL-13, which are crucial in the allergic response, this vaccine targets to modify the patient's immune response to allergens. The promising preclinical results herald a significant breakthrough in allergy treatments, showcasing Neovacs' commitment to expanding its Kinoid technology across different disease states.